THE INVESTIGATION IS STILL IN PROGRESS. ONCE THE INVESTIGATION IS COMPLETE A SUPPLEMENTAL REPORT WILL BE FILED. BM (B)(4) IS ASSOCIATED WITH THIS EVENT. THE INFORMATION PROVIDED BY BARD REPRESENTS ALL OF THE KNOWN INFORMATION AT THIS TIME. DESPITE GOOD FAITH EFFORTS TO OBTAIN ADDITIONAL INFORMATION, THE COMPLAINANT/REPORTER WAS UNABLE OR UNWILLING TO PROVIDE ANY FURTHER PATIENT, PRODUCT, OR PROCEDURAL DETAILS TO BARD.
D
Patient 1
IT WAS REPORTED THAT THE FACILITY RECEIVED SEEDS WITH PRODUCT CODE (B)(4) (SALES ORDER (B)(4)) THAT WERE INTENDED FOR A DIFFERENT FACILITY, INSTEAD OF THE SEEDS THAT WERE ORDERED (1251CSR AND 1251CSRA - SALES ORDER (B)(4)). THE INITIAL INVESTIGATION INTO THE ISSUE INDICATES THAT THE FEDEX LABELS ON THE OUTER SHIPPING BOXES WERE SWITCHED. THE SEEDS THAT THE FACILITY RECEIVED ((B)(4)) WERE REPORTEDLY USED ON THE PATIENT AND THE PATIENT RECEIVED THE CORRECT DOSAGE WITHOUT IMPACT.